Evolent Q4 2024 revenue $646.5M (+16.3% YoY); net loss $30.6M, adjusted EBITDA $22.6M

Evolent Health, Inc.

2024-FY EPS reported -$0.81 revenue$2,554,741,000

Revenue $2,554.7M full year 2024, +30.1% YoY; net loss $93.5M, net loss margin (3.7)%.
Adjusted EBITDA $160.5M full year 2024, margin 6.3%; Q4 adjusted EBITDA $22.6M, margin 3.5%.
Signed contract amendments in all three Performance Suite negotiations, expected $115M annual improvement for 2025 vs Q4 2024.
100% retention across top customers representing over 90% of 2024 revenue; new revenue agreements announced in Q4.
Average Performance Suite lives on platform 7,145 in Q4, average PMPM fee $21.32.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.